Lausanne, Switzerland, July 3, 2023 – AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations at ...

Highly potent in vivo anti-inflammatory activity demonstrated for novel small molecule NLRP3 inhibitors High-affinity antibodies against extracellular components of the inflammasome pathway show ...

Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup ...

Gene‑edited HPSCs programmed to make therapeutic antibodies and proteins show long‑lasting, boostable immunity in mouse models.

AFFiRiS is a clinical-stage biotechnology company located in Vienna, Austria, with a vision of using the immune system to identify and target human proteins central to the development and progression ...

LAUSANNE, Switzerland, May 20, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today ...

- Company to further expand its DECODE™ discovery platform, accelerate multiple oncology clinical programs, and advance discovery programs in oncology, autoimmune disorders, infectious disease, and ...

An innovative gene-editing strategy could establish a new way for the body to manufacture therapeutic proteins—including ...